RALEIGH, N.C., Nov. 10, 2014 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (INC Research) (Nasdaq:INCR), a leading, global Phase I to IV contract research organization (CRO), today rang the opening bell at The Nasdaq Stock Market to celebrate becoming a public company. The Company’s stock began trading Friday, Nov. 7, 2014.
| |||||
A photo accompanying this press release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=28935
CEO Jamie Macdonald was joined by CFO Greg Rush, Chief Administrative Officer & General Counsel Chris Gaenzle, representatives from the Company’s Board of Directors and other members of the INC Research team who have made a significant contribution to the growth of the Company, which provides clinical development services to biopharmaceutical companies worldwide to help bring new medicines to market to patients in need.
“We were proud to ring today’s opening bell on behalf of our employees, our investors and the drug development community in recognition of this significant milestone,” said Mr. Macdonald. “INC Research has become an increasingly significant force in the clinical development industry over the past three years, demonstrating tremendous growth in our capacity and capability to deliver the therapeutic expertise and global clinical development services our biopharmaceutical customers require. Our success could not have been achieved without the passion and contributions of our more than 5,000 employees worldwide who are committed to making life-enhancing drugs a reality for patients around the world. We thank them for their efforts and look forward to this next chapter in our growth that will create even greater opportunities for our stakeholders.”
As a leading global CRO based on revenues, INC Research is exclusively focused on Phase I to IV clinical development services for the biopharmaceutical and medical device industries. Industry sources estimate the market for Phase II to IV clinical development services is expected to grow at a rate of 8 to 9 percent annually through 2018, driven by a combination of increased development spend and further outsourcing penetration. INC Research’s deep therapeutic expertise, global reach and capabilities, and ability to conduct increasingly complex clinical trials and maintain strong site relationships provide the Company with a competitive edge to take advantage of the growing outsourcing trend.
To view the video of the ceremony or for a photo of the Company’s leadership team at the moment the bell rang, please visit the Investor Relations section of the Company’s website at investor.incresearch.com.
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization (CRO) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industry. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. We were ranked “Top CRO to Work With” by sites worldwide in the 2013 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 100 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @inc_research.
The photo is also available via AP PhotoExpress.
CONTACT: Investors: Ronnie Speight +1 919 745 2745 Media: Lori Dorer +1 513 345 1685
Help employers find you! Check out all the jobs and post your resume.
